Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.36 +0.59 (+2.29%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 116,340,158
Open 25.70
Bid (Size) 26.32 (10)
Ask (Size) 26.36 (8)
Prev. Close 25.77
Today's Range 25.70 - 26.49
52wk Range 24.48 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 6.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Via The Motley Fool
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Via The Motley Fool

Performance

YTD
-11.34%
-11.34%
1 Month
+4.89%
+4.89%
3 Month
-10.06%
-10.06%
6 Month
-7.05%
-7.05%
1 Year
-7.18%
-7.18%

More News

Read More
The Stock Market Is Historically Pricey: Here's How I'm Positioning My Portfolio for 2025
Via The Motley Fool
My Top 10 Stocks to Buy for 2025
Via The Motley Fool
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
From Uncertainty to Strength: Navigating Life with Cervical Cancer
Via Brandpoint
Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook
Via Investor's Business Daily
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
Via The Motley Fool
Pfizer Sparks Analyst Cheer With 2025 Guidance: Retail Maintains Extremely Bullish Stance
Via Stocktwits
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Via Investor's Business Daily
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
Via Investor's Business Daily
3 of the Safest Ultra-High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
What's Going On With CVS Health, UnitedHealth And Cigna Group Shares?
Via Benzinga
Topics Government
Exposures Political
Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks
Via Benzinga
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
Via Benzinga
Topics Economy
Exposures Interest Rates
Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025
Via Benzinga
Pfizer Stock Jumps After 2025 Revenue Outlook Offsets $1B Hit From Inflation Reduction Act Changes: Retail’s More Bullish
Via Stocktwits
Topics Economy
Exposures COVID-19 Interest Rates
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
Via Investor's Business Daily
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
From Pfizer Inc.
Via Business Wire
Prediction: 2 Stocks That'll Be Worth More Than Palantir 5 Years From Now
Via The Motley Fool
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.